[go: up one dir, main page]

HK1200088A1 - Methods for reducing the frequency and severity of acute exacerbations of asthma - Google Patents

Methods for reducing the frequency and severity of acute exacerbations of asthma Download PDF

Info

Publication number
HK1200088A1
HK1200088A1 HK15100471.1A HK15100471A HK1200088A1 HK 1200088 A1 HK1200088 A1 HK 1200088A1 HK 15100471 A HK15100471 A HK 15100471A HK 1200088 A1 HK1200088 A1 HK 1200088A1
Authority
HK
Hong Kong
Prior art keywords
antibody
antigen
binding fragment
asthma
patient
Prior art date
Application number
HK15100471.1A
Other languages
English (en)
Chinese (zh)
Inventor
‧摩爾菲諾
N‧摩尔菲诺
‧帕克
J‧帕克
Original Assignee
米迪缪尼有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 米迪缪尼有限公司 filed Critical 米迪缪尼有限公司
Publication of HK1200088A1 publication Critical patent/HK1200088A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK15100471.1A 2011-11-01 2012-10-28 Methods for reducing the frequency and severity of acute exacerbations of asthma HK1200088A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161554110P 2011-11-01 2011-11-01
US61/554,110 2011-11-01
US201161562544P 2011-11-22 2011-11-22
US61/562,544 2011-11-22
US201261645699P 2012-05-11 2012-05-11
US61/645,699 2012-05-11
PCT/US2012/062349 WO2013066780A2 (fr) 2011-11-01 2012-10-28 Procédés de réduction de la fréquence et de la gravité des exacerbations aiguës de l'asthme

Publications (1)

Publication Number Publication Date
HK1200088A1 true HK1200088A1 (en) 2015-07-31

Family

ID=48193002

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15101910.8A HK1201440A1 (en) 2011-11-01 2012-10-28 Methods for reducing the frequency and severity of acute exacerbations of asthma
HK15100471.1A HK1200088A1 (en) 2011-11-01 2012-10-28 Methods for reducing the frequency and severity of acute exacerbations of asthma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15101910.8A HK1201440A1 (en) 2011-11-01 2012-10-28 Methods for reducing the frequency and severity of acute exacerbations of asthma

Country Status (11)

Country Link
US (1) US20140328839A1 (fr)
EP (1) EP2773374A4 (fr)
JP (1) JP2014533246A (fr)
KR (1) KR20140097217A (fr)
CN (1) CN104039352A (fr)
AU (1) AU2012332859A1 (fr)
CA (1) CA2853858A1 (fr)
HK (2) HK1201440A1 (fr)
MX (1) MX2014004968A (fr)
RU (1) RU2014122189A (fr)
WO (1) WO2013066780A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2690675C2 (ru) 2012-08-21 2019-06-05 Санофи Байотекнолоджи Способы лечения или предотвращения астмы посредством введения антагониста il-4r
CN105451760A (zh) 2013-08-12 2016-03-30 米迪缪尼有限公司 使用贝那利珠单抗降低哮喘恶化率的方法
DK3033104T3 (da) * 2013-08-12 2019-06-17 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
SG11201600484TA (en) 2013-08-12 2016-02-26 Medimmune Llc Methods for improving asthma symptoms using benralizumab
EP3485902A1 (fr) * 2013-10-15 2019-05-22 Astrazeneca AB Procédés de traitement de broncho-pneumopathie chronique obstructive à l'aide du benralizumab
CA2926089C (fr) * 2013-10-24 2022-08-30 Medimmune, Llc Formulations d'anticorps aqueuses stables
IL247290B (en) * 2014-02-21 2021-06-30 Sanofi Biotechnology Methods of treating or preventing asthma by adding an il-4r antagonist
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
US20160272706A1 (en) * 2015-01-12 2016-09-22 Medimmune Limited Il-13 binding proteins and uses thereof
US10479836B2 (en) 2015-06-01 2019-11-19 National University Corporation University Of Toyama Method for treating pulmonary hypertension with interleukin-5 receptor antibody
KR20250044796A (ko) 2017-10-30 2025-04-01 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CN111100210B (zh) * 2019-01-30 2022-04-19 武汉九州钰民医药科技有限公司 一种Fc融合蛋白及其应用
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
TW202214692A (zh) 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) * 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
ES2558689T3 (es) * 2007-05-14 2016-02-08 Medimmune, Llc Métodos para reducir los niveles de eosinófilos

Also Published As

Publication number Publication date
MX2014004968A (es) 2014-08-01
WO2013066780A3 (fr) 2013-07-04
US20140328839A1 (en) 2014-11-06
CA2853858A1 (fr) 2013-05-10
RU2014122189A (ru) 2015-12-10
WO2013066780A2 (fr) 2013-05-10
CN104039352A (zh) 2014-09-10
KR20140097217A (ko) 2014-08-06
JP2014533246A (ja) 2014-12-11
EP2773374A4 (fr) 2015-04-29
AU2012332859A1 (en) 2014-05-22
HK1201440A1 (en) 2015-09-04
EP2773374A2 (fr) 2014-09-10

Similar Documents

Publication Publication Date Title
HK1200088A1 (en) Methods for reducing the frequency and severity of acute exacerbations of asthma
CA2918105C (fr) Procedes pour reduire des taux d'exacerbation d'asthme a l'aide de benralizumab
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
Cavaliere et al. The spectrum of therapeutic activity of mepolizumab
JP2024069373A (ja) 視神経脊髄炎の処置のためのエクリズマブ
Virchow et al. Reslizumab as add-on therapy in patients with refractory asthma
HK40064505A (en) Methods for improving asthma symptoms using benralizumab
US20210095037A1 (en) Methods for treating late-onset asthma using benralizumab
WO2021245619A1 (fr) Méthodes pour traiter l'asthme sévère chez des patients souffrant d'une polypose nasale
HK40013807B (en) Methods for improving asthma symptoms using benralizumab
HK40013807A (en) Methods for improving asthma symptoms using benralizumab
HK1225303B (en) Methods for improving asthma symptoms using benralizumab